ReviewMedicinal research reviews2006
Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention.
Review in Medicinal research reviews, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Potential interventions for novel coronavirus in China: A systematic review.Journal of medical virology · 2020Pooled it
- In silico design of a novel multi-epitope mRNA vaccine candidate for BtHKU5-CoV-2 using immunoinformatics.PLoS neglected tropical diseases · 2026Article
- Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches.Biochemistry and biophysics reports · 2024Article
- Potential Drugs in COVID-19 Management.Current medicinal chemistry · 2024Review
- Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines.Signal transduction and targeted therapy · 2023Review
- Micronutrient therapy and effective immune response: a promising approach for management of COVID-19.Infection · 2021Review
- Combination of natural antivirals and potent immune invigorators: A natural remedy to combat COVID-19.Phytotherapy research : PTR · 2021Review
- Development of Coronavirus Treatments Using Neutralizing Antibodies.Microorganisms · 2021Review
- Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19).Microbial pathogenesis · 2020Review
- Article
- Therapeutic strategies for critically ill patients with COVID-19.Annals of intensive care · 2020Review
- Therapeutic Strategies in the Management of COVID-19.Frontiers in molecular biosciences · 2020Review
- COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management.Frontiers in pharmacology · 2020Review
- Article
- Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.Reviews in medical virology · 2012Review
- Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans.PloS one · 2011Article
- Expression of SARS-coronavirus spike glycoprotein in Pichia pastoris.Virus genes · 2009Article
- Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.Antiviral research · 2009Article
- Computational characterization and design of SARS coronavirus receptor recognition and antibody neutralization.Computational biology and chemistry · 2007Article
- Impaired angiogenesis in aminopeptidase N-null mice.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel human coronavirus (CoV) has been identified as the etiological agent that caused the severe acute respiratory syndrome (SARS) outbreak in 2003. The spike (S) protein of this virus is a type I surface glycoprotein that mediates binding of the virus to the host receptor and the subsequent fusion between the viral and host membranes. Because of its critical role in viral entry, the S protein is an important target for the development of anti-SARS CoV therapeutics and prophylactics. This article reviews the structure and function of the SARS CoV S protein in the context of its role in virus entry. Topics that are discussed include: the interaction between the S1 domain of the SARS spike protein and the cellular receptor, angiotensin converting enzyme 2 (ACE2), and the structural features of the ectodomain of ACE2; the antigenic determinants presented by the S protein and the nature of neutralizing monoclonal antibodies that are elicited in vivo; the structure of the 4,3-hydrophobic heptad repeats HR1 and HR2 of the S2 domain and their interaction to form a six-helical bundle during the final stages of fusion. Opportunities for the design and development of anti-SARS agents based on the inhibition of receptor binding, the therapeutic uses of S-directed monoclonal antibodies and inhibitors of HR1-HR2 complex formation are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.